EUCTR2010-023050-37-DE进行中（未招募）不适用
A multicenter, randomized, phase II trial: BIBF 1120 vs. placebo in patients receiving oxaliplatin plus fluorouracil and leucovorin (mFOLFOX6) for advanced, chemorefractory metastatic colorectal cancer (mCRC) - TRICC-C
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients receiving mFOLFOX6 for histologically proven colorectal adenocarcinoma having received one previous line of chemotherapy
- •1. Age > = 18 years
- •2. Histologically proven colorectal adenocarcinoma
- •3. Metastatic disease not suitable for curative intent resection
- •4. Measurable (> 1 cm) and evaluable disease (according to RECIST 1.1 criteria)
- •5. Only one prior palliative chemotherapy for metastatic CRC
- •6. Prior bevacizumab permitted
- •7. No prior TKIs, no prior palliative treatmen twith oxaliplatin
- •8. Previous adjuvant therapy with an oxaliplatin containing regimen is allowed if the end of adjuvant chemotherapy is > 12 months prior to inclusion into the trial
- •9. ECOG performance status 0 or 1
- •10. Adequate hepatic function, renal function, bone marrow function, and lab parameters
- •11. Life expectancy at least three months
- •12. Signed and dated written infromed consent prior to admission to the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 90
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 90
排除标准
- •1. Known hypersensitivity to the trial drugs or their excipients.
- •2. Treatment with any investigational drug within 28 days of trial onset.
- •3. Prior treatment with more than one line of palliative standard chemotherapy for colorectal cancer, prior treatment with a tyrosine kinase inhibitor, prior palliative treatment with an oxaliplatin-containing regime.
- •4. History of other malignancies in the last 5 years, in particular those which could affect compliance with the protocol or interpretation of results. Patients with adequately treated basal or squamous cell skin cancer are generally eligible.
- •5. Serious concomitant disease, especially those that would limit compliance with trial requirements or which are considered relevant for the evaluation of the efficacy or safety of the trial drug, such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with trial participation or trial drug administration, and in the judgment of the investigator would make the patient inappropriate for entry into the trial.
- •6. Major injuries and/or surgery or bone fracture within 4 weeks of trial inclusion, or planned surgical procedures during the trial period.
- •7. Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within past 9 months, congestive heart failure > NYHA II).
- •8. History of severe haemorrhagic or thrombotic events in the past 12 months (excluding central venous catheter thrombosis and peripheral deep vein thrombosis). Known inherited predisposition to bleeds or to thrombosis.
- •9. Patient with brain metastases that are symptomatic and/or require therapy.
- •10. Therapeutic anticoagulation (except low dose heparin and/or heparin flush as needed for maintenance of an indwelling intravenous device) or antiplatelet therapy (except for chronic low-dose therapy with acetylsalicylic acid = 325mg per day)
- •11. History of major thrombotic or clinically relevant major bleeding event in the past 6 months
- •12. Current peripheral neuropathy = CTCAE grade 2 except due to trauma
- •13. Serious infections requiring systemic antibiotic (e.g antiviral, antimicrobial, antifungal) therapy
- •14. Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug
- •15. Active alcohol or drug abuse.
- •16. Women and men who are sexually active and unwilling to use a medically acceptable method of contraception
- •17. Pregnancy or breast-feeding
- •18. Leptomeningeal disease
- •19. Radiographic evidence of cavitary or necrotic tumours
- •20. Centrally located tumours with radiographic evidence (CT or MRI) of local invasion of major blood vessels
研究者
相似试验
进行中（未招募）
1 期
Clinical Trial in patients with glioblastomaEUCTR2014-000838-39-ESGEINO160
进行中（未招募）
不适用
A Phase IIb, 12-week, multicenter, randomized, double-blind, placebo-controlled,pioglitazone-controlled, parallel-group dose-ranging study in approximately 336 maleand female subjects, aged 18 to 70 years with type 2 diabetes mellitus who are treatmentnaïve.Type 2 diabetes mellitusMedDRA version: 8.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2006-004694-97-HUGlaxoSmithKline Research & Development336
进行中（未招募）
1 期
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Early Onset Alzheimer's Disease Caused by a Genetic MutatioEUCTR2013-000307-17-DEWashington University in St. Louis740
进行中（未招募）
1 期
Multicenter randomized phase II study, double-blind, comparing Taxotere plus curcumin versus Taxotere plus placebo combination in first-line treatment of prostate cancer metastatic castration resistantMedDRA version: 14.1Level: LLTClassification code 10066489Term: Progression of prostate cancerSystem Organ Class: 100000004864metastatic prostate cancerEUCTR2013-002138-20-FRCentre Jean Perrin100
进行中（未招募）
2 期
A clinical trial of 5 mg psilocybin plus psychological support vs 25 mg psilocybin plus psychological support in adults with generalised anxiety disorderGeneralised anxiety disorderMental and Behavioural DisordersISRCTN14487299Incannex Healthcare Limited96